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Abstract 
Context: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a poor 
prognosis.  Although the majority of childhood ACC arises in the context of inherited cancer 
susceptibility syndromes, it remains less clear whether a hereditary tumour predisposition exists 
for the development of ACC in adults. Here, we report the first occurrence of familial ACC in 
a kindred with Lynch syndrome due to a pathogenic germline MSH2 mutation.  
 
Case: A 54-year-old female, with a history of ovarian and colorectal malignancy, was found to 
have an ACC. A detailed family history revealed her mother had died of ACC and her sister 
had previously been diagnosed with endometrial and colorectal cancers. A unifying diagnosis 
of Lynch syndrome was considered, and immunohistochemical analyses demonstrated loss of 
MSH2 and MSH6 expression in both adrenocortical carcinomas (proband and her mother), and 
in the endometrial carcinoma of her sister. Subsequent genetic screening confirmed the 
presence of a germline MSH2 mutation (resulting in deletions of exons 1-3) in the proband and 
her sister. 
 
Conclusion: Our findings provide strong support for the recent proposal that ACC should be 
considered a Lynch syndrome associated tumour and included in the Amsterdam II clinical 
diagnostic criteria. We also suggest that screening for ACC should be considered in cancer 
surveillance strategies directed at individuals with germline mutations in DNA mismatch repair 
genes. 
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Introduction  
Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine cancer with an incidence 
of less than 1 case per million individuals per year (1). The majority of childhood ACC occurs 
in patients with familial cancer susceptibility syndromes such as Li-Fraumeni syndrome (LFS), 
but whether a hereditary tumour predisposition exists for the development of ACC in adults is 
less clear (1).  Whilst the majority of ACC in adulthood are sporadic, increasing evidence 
supports association between adult ACC and inherited cancer susceptibility syndromes 
including LFS, Multiple Endocrine Neoplasia type 1 and Lynch syndrome (LS)(1). However, 
given the low prevalence of ACC, ascertaining whether this cancer is a bona fide syndrome-
associated malignancy is challenging.  
 
Lynch syndrome is an autosomal dominant familial cancer syndrome caused by pathogenic 
germline mutations in one of several DNA mismatch repair (MMR) genes (MLH1, MSH2, 
MSH6 or PMS2), and associated with an estimated lifetime colorectal cancer risk of 80% (2).  
LS is also associated with an increased risk of several extra-colonic tumours (endometrial, 
stomach, small intestinal, hepatobiliary, urinary tract), which are therefore included as part of 
the Amsterdam II clinical diagnostic criteria for LS (2). In addition to these recognised cancers, 
previous reports have described a number of rare, non-classical cancers, including 
adrenocortical carcinoma (ACC), in patients with LS. Given the low prevalence of ACC it 
remains uncertain whether it is a true LS-associated tumour or arises independent of the primary 
genetic defect, although a recent study involving 114 subjects with primary ACC and 135 
probands from MMR gene-positive kindreds has provided important evidence for the former 
(3). 
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Here, we provide additional evidence to implicate ACC as a LS-associated cancer with the first 
description of an intergenerational (mother-to-daughter) occurrence of ACC in a family with 
LS due to a germline MSH2 mutation.  We therefore propose that ACC be included in clinical 
diagnostic criteria for LS and considered in cancer surveillance recommendations for 
individuals with germline mutations in DNA MMR genes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
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Case History 
In 2001, the proband (Patient III:2), a 54-year old female, presented to her local hospital with 
right loin pain, lethargy and weight loss. She had previously undergone a hysterectomy and 
bilateral salpingo-oopherectomy for ovarian cancer at age 44 years and endoscopic removal of 
a malignant colonic polyp at age 47 years. Clinical examination revealed right loin tenderness 
but was otherwise unremarkable with no evidence of catecholamine, glucocorticoid, 
mineralocorticoid or androgen excess. Abdominal ultrasonography demonstrated a right 
suprarenal lesion and subsequent computed tomography (CT) confirmed the presence of a 14 
cm mass arising from the right adrenal gland. There was no evidence of extra-adrenal disease. 
Biochemical investigations excluded phaeochromocytoma and confirmed a non-secretory 
adrenal lesion. 
 
The patient underwent a laparoscopic right adrenalectomy and nephrectomy to remove a 14 x 
10cm adrenal mass. Pathological examination of the resected specimen showed an 
adrenocortical tumour with adrenal capsular invasion, areas of confluent necrosis and possible 
vascular invasion (Figure 2A (a) and (b)). The tumour was composed of lobules of oncocytic 
cells separated by fibrous septae. The tumour cells showed focal marked nuclear pleomorphism 
with bizarre nuclear forms. The mitotic index was 1/50hpf. Immunohistochemically, tumour 
cells were positive for vimentin and melan A and negative for calretinin, inhibin, S100, 
cytokeratin, carcinoembryonic antigen (CEA), chromogranin A, neurofilament (NFP) and 
synaptophysin. Collectively, these features were in keeping with an oncocytic adrenocortical 
carcinoma based on Lin-Weiss-Bisceglia criteria (4,5). 
 
Adjunctive mitotane therapy (maximum tolerated dose: 500mg thrice daily) was commenced 
with concurrent hydrocortisone replacement (10mg twice daily). To date the patient has 
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received regular clinical, biochemical and radiological surveillance with no evidence of disease 
recurrence.   
 
The proband’s sister (Patient III:1) had no significant personal medical history until age 36 
years when she was diagnosed with an adenocarcinoma of the descending colon which required 
a left hemicolectomy. At age 47 years she was diagnosed with endometrial carcinoma following 
investigations for intermenstrual bleeding, and treated by radical hysterectomy. 
 
An underlying familial cancer syndrome was suspected and a more detailed family history 
revealed that the proband’s maternal aunt (Patient II:3) and grandfather (Patient I:1) had both 
been diagnosed with colorectal cancer (Figure 1). Importantly, the certificate of death for the 
proband’s mother (Patient II:2) stated metastatic adrenocortical carcinoma as the cause of death. 
Given the rarity and difficulty in establishing malignancy of adrenocortical tumours, the 
histology of the resected adrenal tumour was re-evaluated which, confirmed the original 
diagnosis of primary adrenocortical carcinoma (Figure 2A(c)).  
 
In accordance with the Amsterdam II criteria and revised Bethesda criteria the family fulfilled 
diagnostic requirements for Lynch syndrome and further immunohistochemistry was performed 
on both ACCs (Patients III:2 and II:2) and the endometrial tumour (Patient III:1) to determine 
MMR protein expression status (Figure 2B) (2).  In all analysed tumours expression of MLH1 
and PMS2 was retained whilst nuclear staining for MSH2 and MSH6 were absent, consistent 
with a LS phenotype. Further germline genetic testing was undertaken by multiplex ligation 
dependent probe amplification (MLPA) analysis in the proband and her sister and revealed a 
heterozygous deletion of exons 1, 2 and 3 of the MSH2 gene. Further genetic testing also 
identified the mutation in the proband’s son (Patient IV:5), daughter (Patient IV:4) and niece 
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(Patient IV:2). In accordance with the Chompret testing criteria, TP53 germline mutations were 
excluded in the proband (6). The unavailability of genomic DNA from the proband’s mother 
(Patient II:2) precluded further genetic study.   
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Discussion 
ACC is not currently included in the diagnostic criteria for Lynch syndrome. However, our 
description of familial ACC arising in the context of a germline MSH2 mutation supports the 
recent proposal that ACC should be considered a LS-associated tumour (3). Currently, the 
diagnosis of LS requires patients/kindreds to fulfil the Amsterdam or revised Bethesda criteria, 
with demonstration of absent MMR protein expression on tumour immunohistochemistry 
and/or microsatellite instability (MSI) genotyping supporting the diagnosis (2). Genetic testing 
for germline mutations in MMR genes is reserved for individuals with tumours that demonstrate 
MSI or absent MMR protein expression, or those deemed at-risk based on computational 
prediction models (2).   
 
Isolated cases of ACC arising in single patients of families with LS and germline mutations in 
DNA MMR genes (MLH1, MSH2, MSH6) have been previously reported, but given their rarity, 
determining whether these tumours were coincidental or part of the LS tumour profile has 
remained controversial (3,7,8). Compelling evidence supporting ACC as a LS-associated 
cancer was recently provided by Raymond and colleagues who found that LS prevalence among 
patients with primary ACC was significantly higher (3.2%) than in the background population 
(0.2%), and comparable to the prevalence of LS in colorectal (2-4%) and endometrial cancer 
(1-5%) (3). Moreover, the prevalence of ACC in LS was increased compared with the general 
population. Given that ACC is typically an aggressive malignancy, with limited treatment 
options for advanced disease, recognising association of this tumour with LS has important 
clinical implications. Specifically, improved awareness and recognition of the syndrome and 
entry into appropriate systematic cancer surveillance programmes would be anticipated to lead 
to earlier diagnosis and timely intervention in order to reduce LS-related morbidity and 
mortality.  
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IHC analysis of tumour MMR proteins is often performed concomitantly with MSI to improve 
clinical sensitivity in the evaluation for LS. In our case, IHC analysis for LS-related tumours 
was informative and identified loss of MSH2 and MSH6 expression in the ACC and 
endometrial tumours analysed from affected patients with the germline MSH2 mutation.  In 
contrast with colorectal tumours, which demonstrate high MSI, previous reports have 
consistently found that ACC tumours have low MSI in patients with LS, and on this basis MSI 
testing was not performed in our patient (3). Whilst a molecular basis for this discrepancy 
between tumour types remains unclear, it has been proposed that in some tumours, possibly due 
to tissue-specific factors, the consequences of MMR deficiency occur in the latter stages of 
carcinogenesis thereby preventing detectable accumulation of MSI. Further, currently used MSI 
tests have been optimised for colorectal cancers and are less sensitive for MSI detection in other 
tumour types. Therefore, low MSI does not necessarily exclude a diagnosis of LS and, for both 
sporadic and familial ACC, IHC analysis of MMR proteins should be considered the first-line 
molecular screening strategy, even in individuals without other LS-associated lesions, with 
germline genetic testing pursued in the absence of one or more MMR proteins. Currently, there 
are no established biochemical or radiological screening guidelines for those at-risk of ACC. 
We have adopted an empirical approach in the offspring of our proband, combining periodic 
surveillance MRI imaging MRI with serum and urinary steroid profiling. It remains to be seen 
whether this is a clinically cost-effective approach. 
 
In summary, we report the first description of familial ACC in conjunction with a germline 
MSH2 mutation and provide support for MMR genes as candidates in hereditary ACC. We 
advocate ACC be now included in clinical diagnostic criteria for LS and considered in cancer 
surveillance strategies for individuals with germline mutations in DNA MMR genes. Moreover, 
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in the absence of clinical management guidelines for ACC surveillance in patients with 
inherited cancer syndromes, including LS, we recommend individualised screening protocols 
coupled with ongoing clinical vigilance.  
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Figure Legends 
 
Figure 1. 
Pedigree of family with the germline MSH2 mutation. NN represents wild-type individuals and 
NM denotes carriers of the mutation.  
 
Figure 2. 
(A) (a) High magnification image of H&E stained photomicrograph demonstrating confluent 
tumour necrosis (arrowhead) in ACC from patient II:2. (b) Medium magnification image 
demonstrating capsular invasion (arrowhead) in ACC from patient II:2. (c) Medium 
magnification image of ACC from patient III:2 demonstrating atypical nuclei, mitotic activity 
and areas of necrosis.  
 
(B) Immunohistochemical analyses of MLH1, PMS2, MSH2 and MSH6 protein expression in 
adrenocortical carcinomas (ACC) resected from Patients II:2 (a,b,c,d) and III:2 (e,f,g,h), and 
endometrial tumour resected from Patient III:1 (i,j,k,l) (x400). All analysed tumours retained 
expression of MLH1 (a,e,i) and PMS2 (b,f,j) (short arrowhead) but expression of MSH2 (c,g,k) 
and MSH6 (d,h,l) was absent (solid arrow) with adjacent normal stromal cells exhibiting 
positive staining (dashed arrow). 
